Abliva
Abliva: Potentially faster to market (Redeye)
2020-09-11 12:49
Redeye maintains its fair value of Abliva at SEK 1.4 per share. Optimism around its main asset, KL1333, has increased, but there are still many unknowns concerning clinical outcomes and financing.
info@redeye.se (Redeye.se)
Redeye AB - Redeye.se